XML 35 R23.htm IDEA: XBRL DOCUMENT v3.25.2

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):

			Three Months Ended June 30,												Six Months Ended June 30,
			2025						2024						2025						2024
Total revenue (a)			$	22,241					$	10,797					$	35,434					$	19,901
Cost of product sales			—						176						—						446
Cost of manufacturing services			8,906						2,647						14,306						4,493
Research and development expenses:
Lorigerlimab			10,547						11,009						19,425						20,625
MGC030			5,666						1,636						8,172						4,911
MGC028			4,742						9,678						8,676						15,882
Vobramitamab duocarmazine			4,386						12,038						12,653						21,706
Next-generation T-cell engagers			3,516						2,091						5,789						4,580
MGC026			2,961						3,895						8,914						7,852
MGD024			2,715						2,154						4,907						4,939
Preclinical antibody-drug conjugates (ADCs)			2,058						3,041						3,857						4,364
Margetuximab			437						2,868						756						5,982
Other programs			3,763						3,322						7,340						6,919
Total research and development expenses			40,791						51,732						80,489						97,760
Selling, general and administrative expenses			9,302						14,423						20,020						29,133
Other segment income, net (b)			507						2,517						2,094						4,077
Net loss			$	(36,251)					$	(55,664)					$	(77,287)					$	(107,854)

(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.

(b) Other segment income, net includes interest and other income and interest and other expense.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration